Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

Prof Danie Vermeulen appointed as dean of the Faculty of Natural and Agricultural Sciences
2016-03-18

Description: Prof Danie Vermeulen Tags: Prof Danie Vermeulen

As the new dean of the UFS Faculty of Natural and Agricultural Sciences, Prof Danie Vermeulen is resolute to place this faculty on the world map.
Photo: Anja Aucamp

The Council of the University of the Free State (UFS) approved the appointment of Prof Danie Vermeulen as dean of the Faculty of Natural and Agricultural Sciences during its meeting on 11 March 2016.

“Prof Vermeulen brings to the position of dean a set of formidable research and leadership achievements and a track-record of commitment to equity and diversity in the sciences," said Prof Jonathan Jansen, Vice-Chancellor and Rector of the UFS.

“It is a great honour that was bestowed on me to lead the faculty and it makes me feel very humble," said Prof Vermeulen.

Fifteen years ago, Prof Vermeulen joined the UFS as a researcher and lecturer. From 2007-2009 he filled the role of acting director of the UFS Institute for Groundwater Studies to subsequently be appointed as not only the director of this institute, but also associate Professor in Geohydrology.

As an alumnus, Prof Vermeulen has strong ties to the UFS. He acquired a BSc Honours, MSc, and PhD Cum Laude in Geohydrology here.This pursuit of excellence also transpires in his aspirations for the faculty’s future. “My vision is that the faculty becomes the best in South Africa in various departments – and recognised throughout Africa, especially in the applied sciences. In addition, the faculty will actively interact with world-leading universities, particularly in the hard sciences.”

Prof Vermeulen is a member of the Executive Committee of the Free State branch of the Groundwater Division of South Africa, member of the Executive Council of the International Mine Water Association, as well as council member at the Fossil Fuel Foundation of South Africa. In the past, he has held membership at the International Association of Hydrogeologists, South African Council for Natural Scientific Professions, Ground Water Division of the Geological Society of South Africa, Water Institute of South Africa, FETWATER Groundwater Initiative, and Editorial Board member of the scientific journal, Water SA.

Prof Vermeulen served as the acting dean for six months prior to his appointment. His appointment commences on 1 April 2016 for a period of five year.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept